Solid Tumor Targeting CAR-T Development Service with Chemically Induced Dimerization (CID) System

CID systems represent a pivotal technological advancement in CAR-T therapy by enabling precise, tunable control over T cell activation and signaling, thereby enhancing both the safety and efficacy of therapeutic responses in solid tumors. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with Chemically Induced Dimerization (CID) System engineers next-generation CAR-T cells with spatiotemporal regulation of antitumor activity. Our approach allows for customizable activation kinetics, reduced off-target toxicity, and improved persistence of CAR-T cells within the immunosuppressive tumor microenvironment.

Introduction

CID system is a groundbreaking molecular tool that enables precise, rapid, and reversible control over protein-protein interactions within living cells using small molecules such as rapamycin. In the context of CAR-T therapy for solid tumors, the CID system is ingeniously repurposed to confer spatiotemporal regulation over T cell activation, thereby mitigating on-target/off-tumor toxicity and severe adverse effects like cytokine release syndrome. This innovative approach allows for external, dose-dependent control of therapeutic efficacy, positioning CID-engineered CAR-T cells as a transformative strategy to enhance both the safety and potency of cell-based immunotherapies.

Fig.1 Precision control of cellular processes: chemical-induced dimerization.¹

Solid Tumor Targeting CAR-T Development Service with Chemically Induced Dimerization (CID) System at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with Chemically Induced Dimerization (CID) System enables tunable activation and reversible control of CAR-T cells via small-molecule ligands, allowing precise dose titration and spatial-temporal activity management. Our approach enhances on-target efficacy while minimizing off-tumor toxicity and cytokine-related risks, delivering a safer, more controllable cell therapy candidate.

What We Can Offer

Based on our expertise in immunometabolism, we offer innovative CID-engineered CAR-T platforms that enable precise spatiotemporal control over T cell activation and signaling. Our core strategies include customizable intracellular, transmembrane, and adapter-mediated control systems to enhance safety and efficacy in the solid tumor microenvironment.

Our Service Process

Required Starting Materials:

• Target Antigen Data: High-resolution spatial multi-omics or immunohistochemistry data confirming tumor-specific expression patterns.
• T Cell Source: Patient-derived PBMCs or defined T cell lines for transduction.
• Vector Backbones: Existing plasmids or constructs if available for integration.

Key Steps:

Final Deliverables:

• Comprehensive Project Report: Detailed documentation of vector design, engineering steps, and QC results.
• Functionally Validated iCAR-T Cell Product.

Key Advantages

• Tailored CID Switches: Our customizable CID systems offer highly specific genetic switches that integrate seamlessly with your CAR construct. This design unlocks superior ligand sensitivity and an extended dynamic range for a dependable therapeutic response.
• Reversible & Controllable: By delivering a fully reversible mechanism, we enable precise dose titration and an instant "off switch" for CAR-T activity. This capability is crucial for the rapid clinical management of toxicities, including CRS.

FAQs

Why Choose Us?

Creative Biolabs employs advanced CID technology to pioneer controllable CAR-T solutions for solid tumors. By fusing novel biosensors with modular regulatory systems, we empower real-time and reversible precision control over CAR-T function. This strategy boosts therapeutic potency while drastically reducing off-target effects and CRS risk, ultimately helping to overcome the stubborn barriers in treating solid tumors.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with CID System in our research has significantly improved the safety profile of our lead candidate by virtually eliminating basal activation, which was a major concern with our previous constitutive CAR design." Dr. Al*an.

"The reversible and tightly controlled kinetics provided by their engineered CID systems facilitated accurate Pharmacodynamic (PD) Readouts in our animal models, allowing us to define the therapeutic dosage window with unprecedented precision" M. Chr*n.

"Their ability to design a controllable CAR-T that could be switched on specifically within the challenging in vivo TME environment allowed us to finally demonstrate potent anti-tumor efficacy against a previously refractory solid tumor type." Dr. B. K*r.

How to Contact Us?

Creative Biolabs offers a uniquely integrated solution that combines advanced spatial target mapping with state-of-the-art synthetic biology engineering to support the development of effective, safe, and dose-controllable CAR-T therapies for solid tumors. Enhance the predictability of your lead candidate with unparalleled spatiotemporal precision.

Contact our team to learn more and explore collaboration opportunities for your project.

Reference

1. Czapiński, Jakub et al. "How to Train a Cell-Cutting-Edge Molecular Tools." Frontiers in chemistry vol. 5 12. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fchem.2017.00012.